Quelles complications peuvent survenir avec des anomalies des MAR ?
Les complications incluent des troubles du développement et un risque accru de cancers.
ComplicationsTroubles du développement
#2
Les anomalies des MAR peuvent-elles entraîner des maladies chroniques ?
Oui, certaines anomalies peuvent contribuer à des maladies chroniques comme le cancer.
Maladies chroniquesCancers
#3
Y a-t-il des complications liées aux traitements des MAR ?
Les traitements peuvent avoir des effets secondaires, mais pas spécifiquement liés aux MAR.
Effets secondairesTraitements
#4
Les complications sont-elles réversibles ?
Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes.
RéversibilitéGestion des complications
#5
Les anomalies des MAR affectent-elles la fertilité ?
Certaines anomalies peuvent influencer la fertilité, mais cela dépend du contexte génétique.
FertilitéAnomalies génétiques
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour les anomalies des MAR ?
Les facteurs incluent des prédispositions génétiques et des expositions environnementales.
Facteurs de risquePrédispositions génétiques
#2
L'âge influence-t-il les anomalies des MAR ?
Oui, l'âge avancé peut augmenter le risque de mutations génétiques, y compris dans les MAR.
ÂgeMutations génétiques
#3
Le mode de vie affecte-t-il les MAR ?
Oui, des habitudes comme le tabagisme et l'alimentation peuvent influencer les MAR.
Mode de vieTabagisme
#4
Les antécédents familiaux jouent-ils un rôle ?
Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque d'anomalies.
Antécédents familiauxMaladies génétiques
#5
Les agents environnementaux influencent-ils les MAR ?
Oui, l'exposition à des agents cancérigènes peut affecter l'intégrité des MAR.
Agents environnementauxCancers
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions d'ancrage à la matrice nucléaire : Questions médicales les plus fréquentes",
"headline": "Régions d'ancrage à la matrice nucléaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions d'ancrage à la matrice nucléaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-10",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions d'ancrage à la matrice nucléaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Structures génétiques",
"url": "https://questionsmedicales.fr/mesh/D040342",
"about": {
"@type": "MedicalCondition",
"name": "Structures génétiques",
"code": {
"@type": "MedicalCode",
"code": "D040342",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Régions d'ancrage à la matrice nucléaire",
"alternateName": "Matrix Attachment Regions",
"code": {
"@type": "MedicalCode",
"code": "D045170",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Tian-Yun Wang",
"url": "https://questionsmedicales.fr/author/Tian-Yun%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Xiao-Yin Wang",
"url": "https://questionsmedicales.fr/author/Xiao-Yin%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Yan-Long Jia",
"url": "https://questionsmedicales.fr/author/Yan-Long%20Jia",
"affiliation": {
"@type": "Organization",
"name": "Pharmacy Collage, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Xiao Guo",
"url": "https://questionsmedicales.fr/author/Xiao%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China; International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Lubna Anis",
"url": "https://questionsmedicales.fr/author/Lubna%20Anis",
"affiliation": {
"@type": "Organization",
"name": "Owerko Centre for Children's Neurodevelopment and Mental Health, Alberta Children's Hospital Research Institute, Faculty of Nursing, University of Calgary, Calgary, AB T2N 1N4, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "How To Read a Network Meta-analysis.",
"datePublished": "2023-11-03",
"url": "https://questionsmedicales.fr/article/37925328",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.euf.2023.10.018"
}
},
{
"@type": "ScholarlyArticle",
"name": "Methodological quality of network meta-analysis in dentistry: a meta-research.",
"datePublished": "2023-07-10",
"url": "https://questionsmedicales.fr/article/37436290",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/1807-3107bor-2023.vol37.0062"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of non-pharmacological interventions for adults with subjective cognitive decline: a network meta-analysis and component network meta-analysis.",
"datePublished": "2024-06-27",
"url": "https://questionsmedicales.fr/article/38937777",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12916-024-03491-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Network meta-interpolation: Effect modification adjustment in network meta-analysis using subgroup analyses.",
"datePublished": "2022-11-04",
"url": "https://questionsmedicales.fr/article/36283960",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jrsm.1608"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treatments for alopecia areata: a network meta-analysis.",
"datePublished": "2023-10-23",
"url": "https://questionsmedicales.fr/article/37870096",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD013719.pub2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Régions d'ancrage à la matrice nucléaire",
"item": "https://questionsmedicales.fr/mesh/D045170"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions d'ancrage à la matrice nucléaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions d'ancrage à la matrice nucléaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions d'ancrage à la matrice nucléaire",
"description": "Comment identifier les MAR dans le génome ?\nQuels tests sont utilisés pour étudier les MAR ?\nLes MAR sont-elles visibles par microscopie ?\nPeut-on détecter des mutations dans les MAR ?\nLes MAR sont-elles associées à des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions d'ancrage à la matrice nucléaire",
"description": "Quels symptômes sont liés aux anomalies des MAR ?\nLes MAR affectent-elles l'expression génique ?\nY a-t-il des symptômes associés aux cancers liés aux MAR ?\nLes MAR influencent-elles le développement embryonnaire ?\nLes anomalies des MAR peuvent-elles causer des troubles ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions d'ancrage à la matrice nucléaire",
"description": "Peut-on prévenir les anomalies des MAR ?\nY a-t-il des tests de dépistage pour les anomalies des MAR ?\nComment réduire le risque de cancers liés aux MAR ?\nL'alimentation influence-t-elle les MAR ?\nLes examens médicaux réguliers aident-ils ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions d'ancrage à la matrice nucléaire",
"description": "Y a-t-il des traitements ciblant les MAR ?\nComment les thérapies géniques affectent-elles les MAR ?\nLes traitements du cancer affectent-ils les MAR ?\nPeut-on utiliser des médicaments pour moduler les MAR ?\nLes interventions chirurgicales peuvent-elles affecter les MAR ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions d'ancrage à la matrice nucléaire",
"description": "Quelles complications peuvent survenir avec des anomalies des MAR ?\nLes anomalies des MAR peuvent-elles entraîner des maladies chroniques ?\nY a-t-il des complications liées aux traitements des MAR ?\nLes complications sont-elles réversibles ?\nLes anomalies des MAR affectent-elles la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions d'ancrage à la matrice nucléaire",
"description": "Quels sont les facteurs de risque pour les anomalies des MAR ?\nL'âge influence-t-il les anomalies des MAR ?\nLe mode de vie affecte-t-il les MAR ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes agents environnementaux influencent-ils les MAR ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les MAR dans le génome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les MAR peuvent être identifiées par des techniques de séquençage et d'analyse bioinformatique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier les MAR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme la PCR et l'hybridation in situ sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les MAR sont-elles visibles par microscopie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les MAR ne sont pas directement visibles, mais leur effet sur la structure peut l'être."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les MAR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les MAR peuvent être détectées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Les MAR sont-elles associées à des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines MAR peuvent être liées à des maladies génétiques ou à des cancers."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux anomalies des MAR ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anomalies des MAR peuvent entraîner des dysfonctionnements cellulaires, mais pas de symptômes spécifiques."
}
},
{
"@type": "Question",
"name": "Les MAR affectent-elles l'expression génique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les MAR jouent un rôle crucial dans la régulation de l'expression génique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés aux cancers liés aux MAR ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent du type de cancer, mais peuvent inclure fatigue, douleur, et perte de poids."
}
},
{
"@type": "Question",
"name": "Les MAR influencent-elles le développement embryonnaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les MAR sont impliquées dans la régulation des gènes essentiels au développement embryonnaire."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR peuvent-elles causer des troubles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent contribuer à des troubles du développement ou des cancers."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des MAR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques de maladies associées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests de dépistage pour les anomalies des MAR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de tests de dépistage spécifiques pour les anomalies des MAR."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de cancers liés aux MAR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les facteurs de risque connus comme le tabagisme et l'exposition à des agents cancérigènes."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle les MAR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer l'expression génique, y compris celle des MAR."
}
},
{
"@type": "Question",
"name": "Les examens médicaux réguliers aident-ils ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des maladies associées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblant les MAR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques ciblant les MAR."
}
},
{
"@type": "Question",
"name": "Comment les thérapies géniques affectent-elles les MAR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies géniques peuvent modifier l'expression des gènes associés aux MAR."
}
},
{
"@type": "Question",
"name": "Les traitements du cancer affectent-ils les MAR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements du cancer peuvent influencer l'activité des MAR."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des médicaments pour moduler les MAR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours pour développer des médicaments modulant l'activité des MAR."
}
},
{
"@type": "Question",
"name": "Les interventions chirurgicales peuvent-elles affecter les MAR ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, en modifiant l'environnement cellulaire, mais pas directement les MAR."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des MAR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles du développement et un risque accru de cancers."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR peuvent-elles entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies peuvent contribuer à des maladies chroniques comme le cancer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications liées aux traitements des MAR ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent avoir des effets secondaires, mais pas spécifiquement liés aux MAR."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR affectent-elles la fertilité ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent influencer la fertilité, mais cela dépend du contexte génétique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des MAR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les anomalies des MAR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque de mutations génétiques, y compris dans les MAR."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il les MAR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme et l'alimentation peuvent influencer les MAR."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les agents environnementaux influencent-ils les MAR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des agents cancérigènes peut affecter l'intégrité des MAR."
}
}
]
}
]
}
Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China.
International Joint Research Laboratory for Recombiant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China.
International Joint Research Laboratory for Recombiant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China; International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Owerko Centre for Children's Neurodevelopment and Mental Health, Alberta Children's Hospital Research Institute, Faculty of Nursing, University of Calgary, Calgary, AB T2N 1N4, Canada.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Owerko Centre for Children's Neurodevelopment and Mental Health, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB T2N 1N4, Canada.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Owerko Centre for Children's Neurodevelopment and Mental Health, Alberta Children's Hospital Research Institute, Departments of Pediatrics, Psychiatry, and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
International Joint Research Laboratory for Recombiant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China.
International Joint Research Laboratory for Recombiant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China; International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.
University of Chinese Academy of Sciences, Beijing 100049, China.
Publications dans "Régions d'ancrage à la matrice nucléaire" :
Network meta-analysis (NMA) expands upon traditional meta-analysis by integrating three or more interventions. This allows comparing interventions using evidence from trials that have compared pairs o...
This meta-research aimed to provide an overview of the methodological quality and risk of bias of network meta-analyses (NMA) in dentistry. Searches for NMA of randomized clinical trials with clinical...
Non-pharmacological interventions have a myriad of available intervention options and contain multiple components. Whether specific components of non-pharmacological interventions or combinations are ...
PubMed, Embase, Cochrane, CINAHL, PsycINFO, CENTRAL, Web of Science, and China's two largest databases, CNKI and Wanfang, were searched from inception to 22nd, January 2023. Randomized controlled tria...
A total of 39 trials with 2959 patients were included (range of mean ages, 58.79-77.41 years). Resistance exercise might be the optimal intervention for reducing memory complaints in adults with subje...
The form of physical activity performed appears to be more beneficial than cognitive interventions in reducing subjective memory complaints for adults with subjective cognitive decline, and this diffe...
PROSPERO registry number. CRD42022355363....
Effect modification (EM) may cause bias in network meta-analysis (NMA). Existing population adjustment NMA methods use individual patient data to adjust for EM but disregard available subgroup informa...
Alopecia areata is an autoimmune disease leading to nonscarring hair loss on the scalp or body. There are different treatments including immunosuppressants, hair growth stimulants, and contact immunot...
To assess the benefits and harms of the treatments for alopecia areata (AA), alopecia totalis (AT), and alopecia universalis (AU) in children and adults....
The Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, ClinicalTrials.gov and WHO ICTRP were searched up to July 2022....
We included randomised controlled trials (RCTs) that evaluated classical immunosuppressants, biologics, small molecule inhibitors, contact immunotherapy, hair growth stimulants, and other therapies in...
We used the standard procedures expected by Cochrane including assessment of risks of bias using RoB2 and the certainty of the evidence using GRADE. The primary outcomes were short-term hair regrowth ...
We included 63 studies that tested 47 different treatments in 4817 randomised participants. All trials used a parallel-group design except one that used a cross-over design. The mean sample size was 7...
We found that treatment with baricitinib results in an increase in short- and long-term hair regrowth compared to placebo. Although we found inconclusive results for the risk of serious adverse effect...
Network meta-analysis combines direct and indirect evidence to compare multiple treatments. As direct evidence for one treatment contrast may be indirect evidence for other treatment contrasts, biases...
Evidence has shown that private industry-sponsored randomized controlled trials (RCTs) and meta-analyses are more likely to report intervention-favourable results compared with other sources of fundin...
To (a) explore the recommendation rate of industry-sponsored NMAs on their company's intervention, and (b) assess reporting in NMAs of pharmacologic interventions according to their funding type....
Design: Scoping review of published NMAs with RCTs....
We used a pre-existing NMA database including 1,144 articles from MEDLINE, EMBASE and Cochrane Database of Systematic Reviews, published between January 2013 and July 2018....
NMAs with transparent funding information and comparing pharmacologic interventions with/without placebo....
We captured whether NMAs recommended their own or another company's intervention, classified NMAs according to their primary outcome findings (i.e., statistical significance and direction of effect), ...
We retrieved 658 NMAs, which reported a median of 23 items in the PRISMA-NMA checklist (interquartile range [IQR]: 21-26). NMAs were categorized as 314 publicly-sponsored (PRISMA-NMA median 24.5, IQR ...
Differences in completeness of reporting and author characteristics were apparent among NMAs with different types of funding. Publicly-sponsored NMAs had the best reporting and published their finding...
Therapy for myasthenia gravis (MG) is undergoing a profound change, with new treatments being tested. These include complement inhibitors and neonatal Fc receptor (FcRn) blockers. The aim of this stud...
We assessed statistical heterogeneity across trials based on the Cochrane Q test and I...
We observed an overall mean Myasthenia Gravis-Activities of Daily Living scale (MG-ADL) score change of -2.17 points (95% confidence interval [CI] -2.67, -1.67; p < 0.001) as compared to placebo. No s...
Anti-complement and FcRn treatments both proved to be effective in MG patients, whereas rituximab did not show a significant benefit for patients. Within the limitations of this meta-analysis, includi...
Aerobic exercise is widely recognized for improving mental health and reducing negative emotions, including anxiety. However, research on its role in preventing and treating postpartum depression (PPD...
We conducted a quantitative systematic review of the study in 5 representative databases for the effect of aerobic exercise on PPD. Meta-analysis and network meta-analysis were performed with Review-M...
Twenty-six studies with 2,867 participants were eventually included and the efficacy of aerobic exercise in preventing and treating postpartum depression is significant compared to standard care. (MD ...
The efficacy of aerobic exercise in preventing and treating postpartum depression is significant compared to standard care, with a greater emphasis on prevention. The optimal prescribed exercise volum...
Mounting evidence suggests that breast reduction surgery displays higher rates of surgical site infections (SSI) than initially presumed. Objective of this network meta-analysis is to evaluate the eff...
A network meta-analysis was conducted using a predetermined protocol after searching the electronic databases MEDLINE, Scopus, the Cochrane Library and US National Institutes of Health Ongoing Trials ...
A total of 10 studies was included in the analysis involving 1331 patients. All but one study controlled for major risk factors, and no differences were observed in patients' baseline characteristics....
Antibiotics mitigate the SSI rate after breast reduction. This meta-analysis provides an evidence-based strategy to optimize antibiotic administration. Further research is needed though to examine ant...
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Inst...